pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker NRIX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Relapsed/Refractory B-cell Mali
Brisbane, USA HQ
2012 Founded
350 Employees
Public company Type
NRIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
NX-2127
Phase 1 · small molecule · Chronic Lymphocytic Leukemia (CLL)
NX-2127 for Chronic Lymphocytic Leukemia (CLL) is a Phase 1 program (small_molecule) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code NX-2127-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nurix Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Chronic Lymphocytic Leukemia (CLL)
- Status
- active
- Trials
- 1